UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/010,723	12/06/2001	Mark G. Allen	BVTP-P04-506	4309	
28120	7590 06/23/2006		EXAM	EXAMINER	
FISH & NEAVE IP GROUP			WITCZAK, CATHERINE		
ROPES & GRAY LLP ONE INTERNATIONAL PLACE			ART UNIT	PAPER NUMBER	
BOSTON, MA	A 02110-2624		3767		
			DATE MAILED: 06/23/2006	5	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/010,723	ALLEN ET AL.				
Office Action Summary	Examiner	Art Unit				
	Catherine N. Witczak	3767				
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the	correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATIO 36(a). In no event, however, may a reply be ti will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONI	N. mely filed the mailing date of this communication. ED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 21 A	<i>pril 2006</i> .					
· · · · · · · · · · · · · · · · · · ·						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under be	Ex parte Quayle, 1935 C.D. 11, 4	53 O.G. 213.				
Disposition of Claims						
. 4)⊠ Claim(s) <u>1 and 49-72</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdra						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1 and 49-72</u> is/are rejected.	•					
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/o	or election requirement.					
Application Papers						
9) The specification is objected to by the Examine	er.					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the	drawing(s) be held in abeyance. Se	ee 37 CFR 1.85(a).				
Replacement drawing sheet(s) including the correct						
11) ☐ The oath or declaration is objected to by the E	xaminer. Note the attached Office	e Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Bureat * See the attached detailed Office action for a list 	ts have been received. ts have been received in Applicatority documents have been received in Rule 17.2(a)).	tion No red in this National Stage				
Attachment(s) 1) X Notice of References Cited (PTO-892)	4) Interview Summar					
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 	Paper No(s)/Mail I 5) Notice of Informal 6) Other:	Pate Patent Application (PTO-152)				

Part of Paper No./Mail Date 20060620

Application/Control Number: 10/010,723

Art Unit: 3767

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR

1.17(e), was filed in this application after final rejection. Since this application is eligible for continued

examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the

finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's

submission filed on 4/21/2006 has been entered.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis

for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on

sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1 and 49-70 are rejected under 35 U.S.C. 102(b) as being anticipated by Gerstel et al (US 1.

3,964,482).

Claims 1, 49-61, and 70: Gerstel et al disclose in column 7, lines 52-68 the microneedle having a length

between 1um and 1mm and a diameter between 1um and 100um with an annular channel extending from

the base to the tip (Figure 1), having either a conical or tapered tip (Figures 1 and 2) and being angled at

about 90. Gerstel et al further disclose in columns 10-11 the substrate (14) and/or the microneedle being

formed from flexible materials.

www (20/00

Page 2

Art Unit: 3767

Claims 62-68: Gerstel et al disclose in column 8, lines 30-60, column 9, lines 29-35 and column 10, lines

55-column 11, lines 63 that the microneedles can be made of a material consisting of a metal, and metal

alloy, a biodegradable polymer or a non-biodegradable polymer.

Claim 69: Gerstel et al disclose in column 8, line 60-column 9, line 41 and column 11, lines 20-51 the

microneedles can be formed by a micromachining technique selected from lithography, etching, thermal

oxidation of silicon, electroplating, electroless plating, diffusion, ion implantation, film deposition,

sputtering, chemical vapor deposition, epitaxy, or anodization.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness

rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are

such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the

manner in which the invention was made.

2. Claim 72 is rejected under 35 U.S.C. 103(a) as being unpatentable over Gerstel et al as modified

by Eicher et al (US 6,132,755).

Gerstel et al disclose the claimed invention except a transport control mechanism for generating a

voltage field gradient for causing the material to move across a biological barrier. Eicher et al discloses a

transport control mechanism for generating a voltage field gradient for causing the material to move

across a biological barrier in column 5, lines 48 - column 6, line 8. It would have been obvious to one

with ordinary skill in the art to modify the system as taught by Gerstel et al with a transport control

mechanism for generating a voltage field gradient for causing the material to move across a biological

W

Art Unit: 3767

barrier as taught by Eicher et al since such a modification would increase the migration of the drug across the skin barrier and improve absorption.

3. Claim 72 is rejected under 35 U.S.C. 103(a) as being unpatentable over Gerstel et al as modified by Godshall et al (US 5,879,326).

Gerstel et al disclose the claimed invention except a transport control mechanism for generating an ultrasonic force gradient for causing the material to move across a biological barrier. Godshall et al discloses a transport control mechanism for generating an ultrasonic force gradient for causing the material to move across a biological barrier in column 2, lines 7-16. It would have been obvious to one with ordinary skill in the art to modify the system as taught by Gerstel et al with a transport control mechanism for generating an ultrasonic force gradient for causing the material to move across a biological barrier as taught by Godshall et al since such a modification would increase the migration of the drug across the skin barrier and improve absorption.

Response to Arguments

4. Applicant's arguments with respect to claims 1 and 49-72 have been considered but are moot in view of the new ground(s) of rejection.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Catherine N. Witczak whose telephone number is (571) 272-7179. The examiner can normally be reached on Monday through Friday, 8-5 EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Kevin Sirmons can be reached on (571) 272-4965. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/010,723

Art Unit: 3767

Page 5

Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available For more information about the PAIR system, see http://pairthrough Private PAIR only. direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic

Information regarding the status of an application may be obtained from the Patent Application

Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer

Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR

CANADA) or 571-272-1000.

mmm 1/10000

KEVIN C. SIRMONS

SUPERVISORY PATENT EXAMINER

Phuri C- bermon